...
首页> 外文期刊>Scandinavian journal of infectious diseases. >Mutations in the NS5A gene predict response to interferon therapy in Japanese patients with chronic hepatitis C and cirrhosis.
【24h】

Mutations in the NS5A gene predict response to interferon therapy in Japanese patients with chronic hepatitis C and cirrhosis.

机译:NS5A基因的突变可预测日本慢性丙型肝炎和肝硬化患者对干扰素治疗的反应。

获取原文
获取原文并翻译 | 示例

摘要

The virus genotype, serum HCV-RNA level and liver histology are reported to be important factors in the response to interferon therapy. Recent studies have revealed that HCV NS5A 2209-2248 amino acid changes affect the response to interferon therapy of genotype 1b chronic hepatitis C. In contrast, some studies done in western countries have reported no such correlation. In the present study, interferon therapy was given to 58 Japanese patients, including 15 liver cirrhosis patients. NS5A 2209-2248 changes, the serum HCV level, ALT level, age and histology were examined in relation to the interferon effect. Twenty-four of the 58 patients (41%) showed a sustained virological response to the therapy. The responses to interferon therapy were significantly correlated with NS5A 2209-2248 changes (p < 0.0001), the HCV-RNA level (p < 0.0001) and histology (p < 0.0060). Among 15 liver cirrhosis patients, 3 of 6 mutant type patients showed a sustained virological response; 5 intermediate and 4 with wild type virus infected patients showed no responses. In conclusion, NS5A 2209-2248 changes may be a useful predictive marker of response to interferon therapy in addition to the serum HCV RNA level even in histologically advanced patients.
机译:据报道,病毒基因型,血清HCV-RNA水平和肝组织学是干扰素治疗反应的重要因素。最近的研究表明,HCV NS5A 2209-2248的氨基酸变化会影响基因型1b慢性丙型肝炎对干扰素治疗的反应。相比之下,西方国家进行的一些研究报告没有这种相关性。在本研究中,对58例日本患者进行了干扰素治疗,其中包括15例肝硬化患者。检查NS5A 2209-2248的变化,血清HCV水平,ALT水平,年龄和组织学与干扰素作用的关系。 58名患者中有24名(41%)对治疗表现出持续的病毒学应答。干扰素治疗的反应与NS5A 2209-2248的变化(p <0.0001),HCV-RNA水平(p <0.0001)和组织学(p <0.0060)显着相关。在15例肝硬化患者中,6例突变型患者中有3例表现出持续的病毒学应答。 5名中型和4名野生型病毒感染患者未显示反应。总之,NS5A 2209-2248的变化可能是对干扰素治疗反应的有用预测指标,除了血清HCV RNA水平外,甚至在组织学晚期的患者中也是如此。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号